Back

Transendocardial injection of autologous expanded CD34+ Stem Cells (ProtheraCytes) promotes reverse cardiac remodeling in patients with left ventricular dysfunction after acute myocardial infarction

14 May 2024 (08:30 - 08:38)
Organised by: Logo
Congress Presentation Part of: Late breaking clinical trials II Clinical HFA Premium Access Heart Failure 2024 Heart Failure Association (HFA)

About the speaker

Photo
Professor Faiez Zannad

University of Lorraine, Vandoeuvre-Les-Nancy (France)

9 More presentations in this session

Presentation thumbnail
Discussant review - EXCELLENT
Professor F. Gustafsson (Pleasanton, US)
Slides Video
Presentation thumbnail
Bio-ADM as a marker for residual congestion and early rehospitalization in patients hospitalized for acute heart failure; data from STRONG-HF
Mr G. Voordes (Groningen, NL)
Slides Video
Presentation thumbnail
Discussant review - STRONG-HF
Professor A. Bayes Genis (Badalona, ES)
Slides Video
Presentation thumbnail
Semaglutide and cardiovascular outcomes in patients with overweight or obesity and heart failure: A pre-specified analysis from the SELECT trial
Professor J. Deanfield (London, GB)
Slides Video
Presentation thumbnail
Discussant review - SELECT
Professor P. Jhund (Glasgow, GB)
Slides Video

Access the full session

Session thumbnail
Late breaking clinical trials II
Video

The Event

Event poster

Heart Failure 2024

14 May 2024 08:30 CET
You may be interested in
thumbnail
Congress Presentation
Discussant review - EXCELLENT
thumbnail
Congress Presentation
Cell therapy in heart failure: lessons learned and future directions
thumbnail
Congress Session
Advanced therapies in heart failure

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources